"HIV Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
| Descriptor ID |
D015488
|
| MeSH Number(s) |
D23.050.327.520
|
| Concept/Terms |
HIV Antigens- HIV Antigens
- Antigens, HIV
- AIDS Antigens
- Antigens, AIDS
- HIV Associated Antigens
- Antigens, HIV Associated
- Associated Antigens, HIV
- HIV-Associated Antigens
- Antigens, HIV-Associated
- HTLV III Antigens
- Antigens, HTLV III
- III Antigens, HTLV
- T Lymphotropic Virus Type III Antigens, Human
- HTLV III LAV Antigens
- HTLV-III-LAV Antigens
- Antigens, HTLV-III-LAV
- LAV Antigens
- Antigens, LAV
- Lymphadenopathy Associated Antigens
- Antigens, Lymphadenopathy Associated
- Associated Antigens, Lymphadenopathy
- Lymphadenopathy-Associated Antigens
- Antigens, Lymphadenopathy-Associated
- T-Lymphotropic Virus Type III Antigens, Human
- HTLV-III Antigens
- Antigens, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Antigens".
Below are MeSH descriptors whose meaning is more specific than "HIV Antigens".
This graph shows the total number of publications written about "HIV Antigens" by people in this website by year, and whether "HIV Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Antigens" by people in Profiles.
-
Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy. J Clin Microbiol. 2022 12 21; 60(12):e0120422.
-
Evolution of an Electronic Health Record Based-Human Immunodeficiency Virus (HIV) Screening Program in an Urban Emergency Department for Diagnosing Acute and Chronic HIV Infection. J Emerg Med. 2019 11; 57(5):732-739.
-
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71.
-
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
-
Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010 Feb; 7(1):4-10.
-
Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1. J Virol. 2002 Oct; 76(20):10219-25.
-
A look at HIV immune research. Interview by Alan Huff. Res Initiat Treat Action. 2000 Sep; 6(3):30-3.
-
Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1713-5.
-
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
-
Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. AIDS. 1996 Jun; 10(6):603-11.